Development of antibodies and chimeric molecules for cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Monoclonal antibodies represent a rapidly growing class of cancer therapeutics.
• Several monoclonal antibodies targeting specific cancers like non-Hodgkin's lymphoma (NHL) and metastatic breast cancer have gained FDA approval.
• Current research focuses on novel targets such as growth factor receptors and immune checkpoints.

Purpose of the Study:

• To review the advancements in monoclonal antibody therapy for cancer.
• To highlight the expanding applications and improved efficacy of antibody-based treatments.
• To discuss future directions in antibody engineering and targeting strategies.

Main Methods:

• Review of FDA-approved monoclonal antibodies for cancer treatment.
• Analysis of genetic engineering techniques to enhance antibody effector functions (e.g., antibody-dependent cellular cytotoxicity).
• Examination of antibody-drug conjugates and other "armed" antibody strategies.

Main Results:

• Nineteen therapeutic monoclonal antibodies are now FDA-approved, with eight specifically for cancer treatment.
• Genetic modifications have significantly improved antibody efficacy and effector functions.
• Antibodies armed with payloads like cytokines, toxins, and radionuclides demonstrate augmented tumor cytotoxicity.

Conclusions:

• Monoclonal antibodies have become a cornerstone in neoplasia therapy.
• Ongoing innovation in antibody design and targeting promises further improvements in cancer treatment outcomes.
• The strategic use of engineered and armed antibodies offers a powerful approach to combatting various cancers.